The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals.

Here's where Dr. David Eifrig says to move your money immediately.

Jennifer Michaelson net worth and biography

Jennifer Michaelson Biography and Net Worth

Insider of Cullinan Oncology

Jennifer is Chief Development Officer, Biologics at Cullinan.

Prior to joining Cullinan, Jennifer served as Senior Director and Executive Program Leader at Jounce Therapeutics, where she led the flagship ICOS antibody program, JTX-2011, from inception into Phase 2 development. An employee since company launch, Jennifer built and led multiple departments at Jounce, including Tumor Immunology, Pharmacology, and Preclinical Development. Jennifer was also a member of the Leadership Team at Jounce.

Previously, during her 10 year tenure at Biogen, Jennifer served as project leader for several monoclonal antibody and bispecific antibody programs in both the Oncology and Immunology therapeutic areas. Jennifer has also worked as a consultant at Third Rock Ventures for multiple stealth companies.

Jennifer received her B.A. in Biology from Princeton University and Ph.D from the Department of Cell Biology at Albert Einstein College of Medicine, and completed a post-doctoral fellowship in Philip Leder’s laboratory in the Department of Genetics at Harvard Medical School.

What is Jennifer Michaelson's net worth?: The estimated net worth of Jennifer Michaelson is at least $2.25 million as of December 12th, 2023. Dr. Michaelson owns 88,965 shares of Cullinan Oncology stock worth more than $2,250,815 as of April 26th. This net worth estimate does not reflect any other investments that Dr. Michaelson may own. Learn More about Jennifer Michaelson's net worth.
How old is Jennifer Michaelson?: Dr. Michaelson is currently 57 years old. There are 5 older executives and no younger executives at Cullinan Oncology. The oldest executive at Cullinan Oncology is Dr. Patrick A. Baeuerle Ph.D., Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board, who is 66 years old. Learn More on Jennifer Michaelson's age.
How do I contact Jennifer Michaelson?: The corporate mailing address for Dr. Michaelson and other Cullinan Oncology executives is , , . Cullinan Oncology can also be reached via phone at 617-410-4650 and via email at [email protected]. Learn More on Jennifer Michaelson's contact information.
Has Jennifer Michaelson been buying or selling shares of Cullinan Oncology?: Jennifer Michaelson has not been actively trading shares of Cullinan Oncology over the course of the past ninety days. Most recently, Jennifer Michaelson sold 1,068 shares of the business's stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $7.81, for a transaction totalling $8,341.08. Following the completion of the sale, the insider now directly owns 88,965 shares of the company's stock, valued at $694,816.65. Learn More on Jennifer Michaelson's trading history.
Who are Cullinan Oncology's active insiders?: Cullinan Oncology's insider roster includes Nadim Ahmed (Pres), Ansbert Gadicke (Director), Jennifer Michaelson (Insider), Jeffrey Trigilio (CFO), and Leigh Zawel (Insider). Learn More on Cullinan Oncology's active insiders.
Are insiders buying or selling shares of Cullinan Oncology?: During the last twelve months, insiders at the sold shares 21 times. They sold a total of 126,339 shares worth more than $1,727,655.68. The most recent insider tranaction occured on February, 1st when insider Corrine Savill sold 40,000 shares worth more than $647,200.00. Insiders at Cullinan Oncology own 8.8% of the company. Learn More about insider trades at Cullinan Oncology.
Information on this page was last updated on 2/1/2024.

Jennifer Michaelson Insider Trading History at Cullinan Oncology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/12/2023	Sell	1,068	$7.81	$8,341.08	88,965
6/12/2023	Sell	176	$13.11	$2,307.36	90,271
6/6/2023	Sell	11,900	$12.31	$146,489.00	90,447
5/18/2023	Sell	239	$8.76	$2,093.64	90,447
5/12/2023	Sell	193	$8.78	$1,694.54	90,686
4/12/2023	Sell	176	$10.22	$1,798.72	91,117
11/25/2022	Sell	4,000	$13.30	$53,200.00	53,031
9/27/2022	Sell	4,000	$12.40	$49,600.00	53,031
7/25/2022	Sell	8,000	$14.51	$116,080.00	53,031
10/18/2021	Sell	4,000	$21.42	$85,680.00
9/20/2021	Sell	4,000	$24.51	$98,040.00

Jennifer Michaelson Buying and Selling Activity at Cullinan Oncology

Cullinan Oncology Company Overview

Cullinan Oncology, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $25.30

$19.27

$25.72

50 Day Range

MA: $17.18

$15.32

$19.25

2 Week Range

Now: $25.30

$7.64

$25.72

Volume

4,747,157 shs

Average Volume

556,302 shs

Market Capitalization

$1.09 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.33

Move Your Money Before May 22

From Stansberry Research | Ad